NCT04026958View on ClinicalTrials.gov

Clarithromycin Mechanisms in Hypersomnia Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions
Narcolepsy Without CataplexyIdiopathic HypersomniaNarcolepsy With Cataplexy
Interventions
DRUG

Clarithromycin

Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.

DRUG

Placebo

A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.

Trial Locations (1)

30329

Emory Sleep Center, Atlanta

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Emory University

OTHER

NCT04026958 - Clarithromycin Mechanisms in Hypersomnia Syndromes | Biotech Hunter | Biotech Hunter